180-day efficacy of nirsevimab against hospitalisation for respiratory syncytial virus lower respiratory tract infections in infants (HARMONIE): a randomised, controlled, phase 3b trial
Authors
Karine Mari
Helen Hill (ORCID: https://orcid.org/0000-0002-7340-4802)
Simon B. Drysdale (ORCID: https://orcid.org/0000-0002-6350-6557)
European Society for Paediatric Infectious Diseases
Moderna
National Institute for Health and Care Research
Sanofi Pasteur
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article
180-day efficacy of nirsevimab against hospitalisation for respiratory syncytial virus lower respiratory tract infections in infants (HARMONIE): a randomised, controlled, phase 3b trial
Karine Mari, Helen Hill, Simon B. Drysdale, M.N.P. Carreño et al.
Citations
36 citations
Journal
The Lancet Child & Adolescent Health
Topics
Respiratory viral infections research
Field-Weighted Citation Impact (FWCI)
48.75
article
180-day efficacy of nirsevimab against hospitalisation for respiratory syncytial virus lower respiratory tract infections in infants (HARMONIE): a randomised, controlled, phase 3b trial
Karine Mari, Helen Hill, Simon B. Drysdale, M.N.P. Carreño, Pierre Bourron, Florence Flamein, Markus Knuf, Natalya Vassilouthis, Simon Royal, Friedrich Kaiser, Andrea M. Collins, Alasdair Munro, Katrina Cathie, Michelle Roberts, Saul N. Faust, Didier Pinquier, Jonathan Cohen, Catherine Moreau, Pierre Tissières, Lydie Marcelon
article en
36 citations
Abstract
No abstract available for this paper.
Publication Tag
The Lancet Child & Adolescent HealthVol. 9(6)
Institutions
University of Nottingham (GB), Liverpool School of Tropical Medicine (GB), Sanofi (France) (FR), Hôpital Charles-Nicolle (FR), Klinik und Poliklinik für Kinder- und Jugendmedizin (DE), Sanofi (United States) (US), Praxis für Humangenetik (DE), Association Clinique et Thérapeutique Infantile du Val de Marne (FR), Sanofi (United Kingdom) (GB), Hôpital Intercommunal de Créteil (FR)
Funders
Pfizer, AstraZeneca, GlaxoSmithKline, Sanofi, European Society for Paediatric Infectious Diseases, Moderna, National Institute for Health and Care Research, Sanofi Pasteur